ストックスクリーナーアプリを入手
1.06
0.00%
0.00
アフターアワーズ：
1.05
-0.01
-0.94%
Pds Biotechnology Corp (PDSB) 最新ニュース
PDS Biotech to Discuss First Quarter 2026 Financial Results on May 6th - geneonline.com
PDS Biotech to give Q1 results and clinical update May 13 - Stock Titan
- SEC.gov
PDS Biotechnology Refinances Debt with New Note, Warrant - TipRanks
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April - MarketBeat
PDSB Stock Price, Quote & Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDSB Stock Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Corporation announced that it expects to receive $5.76 million in funding - marketscreener.com
[EFFECT] PDS Biotechnology Corp SEC Filing - Stock Titan
PDS Biotech 2025 Executive Compensation, Leadership Structure, and Equity Ownership Overview - Minichart
[10-K/A] PDS Biotechnology Corp Amends Annual Report - Stock Titan
PDS Biotechnology (NASDAQ: PDSB) registers $200M shelf, removes $20M ATM - Stock Titan
PDS Biotechnology: FDA-Alignment für VERSATILE-003 - Börse Global
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment - MSN
PDS Biotechnology updates corporate presentation highlighting Phase 3 VERSATILE-003, 39.3m mOS and upcoming catalysts - TradingView
PDS Biotech (NASDAQ: PDSB) spotlights PDS0101 Phase 3 and IL-12 ADC - Stock Titan
PDS (PDSB) Stock Analysis: Buy or Sell? | PDS Biotechnology Corporation posts 24.4% EPS beatSocial Buzz Stocks - Xã Thanh Hà
Form DEF 14AOther definitive proxy statements - ADVFN
PDSB: Positive Data from Phase 2 Trial of PDS01ADC Published - GuruFocus
PDSB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15.00 - GuruFocus
PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright - MarketBeat
Why Is PDS Biotechnology Stock Gaining Wednesday?PDS Biotechnology (NASDAQ:PDSB) - Benzinga
PDS Biotech’s PDS01ADC Shows 78% Response Rate in Phase 2 Metastatic Colorectal Cancer Trial, Published in JCO Oncology Advances - Minichart
PDS Biotech reports 78% response rate in colorectal cancer trial - Investing.com
PDS Biotech reports 78% response rate in colorectal cancer trial By Investing.com - Investing.com South Africa
Interim PDS01ADC data lift responses in tough mCRC for PDS Biotech (PDSB) - Stock Titan
PDS Biotechnology Announces Promising Phase 2 Trial Results of PDS01ADC for Treatment of Colorectal Liver Metastases - Quiver Quantitative
In a 9-patient colon cancer study, PDS drug showed 78% response - Stock Titan
Aug Drivers: Is PDS Biotechnology Corporation trading at a discount2026 Earnings Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Is PDS (PDSB) Stock Expanding | Price at $1.09, Up 0.93%Trending Social Stocks - Newser
Is PDS (PDSB) Stock Declining | Price at $0.76, Up 19.06%Seasonal Patterns - Newser
What is HC Wainwright’s Estimate for PDSB FY2026 Earnings? - Defense World
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript - Insider Monkey
PDSB Should I Buy - intellectia.ai
PDS Biotechnology Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
PDS Biotechnology Corp 2025 Annual Report: Versamune® Immunotherapy Pipeline, Clinical Results, and Executive Leadership Overview - Minichart
PDS Biotech amends phase 3 trial to speed approval timeline By Investing.com - Investing.com South Africa
PDS Biotech Reports 2025 Financial Results and Advances PDS0101 Phase 3 Program with Accelerated Approval Pathway - Minichart
PDS Biotech (NASDAQ: PDSB) details trial progress and $26.7M cash - Stock Titan
Form 10-K PDS Biotechnology Corp For: Dec 31 - StreetInsider
PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap - AlphaStreet
PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings - AlphaStreet
PDSB: Net loss narrowed, clinical trials advanced, and new patents extended exclusivity into the 2040s - TradingView
Bicara Therapeutics 2025 Financial Update - AlphaStreet
Earnings call transcript: PDS Biotech’s Q4 2025 results show improved financial discipline - Investing.com
PDS Biotech amends phase 3 trial to speed approval timeline - Investing.com
PDS Biotechnology: Q4 Earnings Snapshot - marketscreener.com
Phase 3 trial shift and cash update for PDS Biotech (NASDAQ: PDSB) - Stock Titan
PDS Biotech Reports Full Year 2025 Financial Results and - GlobeNewswire
PDS Biotechnology FY 2025 earnings preview - MSN
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement - Bitget
Published on: 2026-03-28 11:50:07 - baoquankhu1.vn
Aug Breakouts: Whats the analyst consensus on PDS Biotechnology CorporationMarket Trend Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results - The Manila Times
1.77%
0.25%
大文字化:
|
ボリューム (24 時間):